This is a patient who had an anterior cervical discectomy and fusion (ACDF). The left sided MRI shows a disc at cervical level C5-6 pushing on the spinal cord. The disc is is removed leaving a space which is filled by the titanium interbody spacer seen on the post-operative x-ray. Certain insurance companies are not reimbursing the interbody spacer.

Post-operative spine patient

One of the most common and effective surgeries for cervical degeneration causing neck pain or radiating arm symptoms is an anterior cervical discectomy and fusion (ACDF).

Yet some insurance companies categorically refuse to reimburse for the interbody device spacers used in a portion of the procedure under the CPT billing code 22853. Payers label them “experimental” or “not medically necessary” when compared with cadaver donor bone called structural allograft. Such policies reach far beyond isolated coverage disputes. They exemplify a deeper systemic dysfunction in which third-party payers insert themselves into granular clinical decision-making, overriding contemporary peer-reviewed evidence and now a new unanimous professional consensus from major spine societies.

This raises a critical question: how much oversight should payers be allowed to exercise over the actual delivery of healthcare?

Why Patients Undergo An Anterior Cervical Discectomy And Fusion (ACDF)?

Patients typically seek spine surgeons when cervical discs degenerate, herniate, or develop osteophytes (bony overgrowth) that compress the spinal cord or exiting nerve roots going to the arms. This results in radiating arm pain (radiculopathy), numbness, tingling, hand weakness, or myelopathy manifesting as balance issues and coordination deficits. While most individuals with this cervical spondylosis improve with conservative care, those experiencing progressive neurologic decline or intractable pain after exhaustive nonoperative treatment—physical therapy, medications, injections, and activity modification—often require surgical decompression and stabilization. The primary goals are restoring neurologic function, alleviating pain if possible and safeguarding the spinal cord so patients can resume meaningful daily activities.

What Is An ACDF Spine Surgery?

ACDF is a well-established, highly reproducible procedure in which the surgeon accesses the cervical spine through a small anterior front of the neck incision. After careful retraction of soft tissues, the surgeon performs a complete discectomy, removes compressive bone spurs or disc material, and thoroughly decompresses the spinal cord and nerve roots. An interbody spacer or graft, typically supplemented with a plate, restores the physiologic space where the disc was and maintains alignment, enabling the joint to achieve solid bony fusion (bone healing). Performed under general anesthesia, ACDF provides reliable, durable relief for appropriately selected patients.

What Is An Interbody Device?

After disc removal, the resulting interspace requires robust reconstruction to restore height, alignment, and stability. Interbody options vary significantly in material properties, biologic behavior, radiographic characteristics, and cost.

1) Titanium interbodies, especially modern 3D-printed porous designs, provide exceptional strength and promote direct osseointegration (bone growth), often yielding lower subsidence and revision rates, though metallic artifact can complicate imaging. They also tend to be more expensive.

2) PEEK (polyetheretherketone) interbodies are radiolucent polymer cages with an elastic modulus similar to cortical bone. More compliant than metal, they reduce stress shielding and support excellent MRI/CT fusion assessment, but their long-term data for bone healing, especially in multiple level cases is guarded at best. Newer hydroxyapatite-coated (bone coated) versions seek to enhance integration and may show significant promise for patients.

3) Structural allograft, machined from donor bone cadaver (commonly fibula or iliac crest), is a safe alterative. It can however exhibit variable mechanical properties and higher pseudoarthrosis rates in select series. It tends to be the cheapest option.

Each option carries distinct advantages and trade-offs. Modern cages frequently outperform allograft in segmental height maintenance and lordosis preservation, with peer-reviewed evidence showing lower subsidence (non-healing) and comparable or superior fusion rates. Both allograft and biomechanical devices are evidence-based options; optimal selection should arise from individualized surgeon-patient discussion based on anatomy, bone quality, comorbidities, and values—not distant claims reviewers.

Why Would An Insurer Decline Payment for Interbody Devices?

Payers face relentless pressure to control costs within the healthcare system. Structural allograft is less expensive upfront. Some studies show similar short-term patient-reported outcomes between allograft and cage cohorts, and insurers reasonably ask whether the added expense of a manufactured device justifies routine use. They worry about overutilization and demand higher-quality comparative-effectiveness data before expanding coverage. In an era of rising premiums and strained public budgets, that skepticism is not inherently unreasonable.

Moral hazard remains one of the most significant distortions in modern healthcare. When third-party payers cover the vast majority of costs, neither patients nor surgeons fully internalize the marginal expense of selecting premium interbody devices over clinically acceptable lower-cost alternatives. Insurers therefore have both a fiduciary right and a legitimate financial responsibility to deny routine reimbursement for such devices when less expensive options like structural allograft can achieve comparable outcomes, thereby curbing the natural tendency toward unchecked escalation of healthcare spending.

However, in this specific instance, this stance weakens under closer examination. Interbody devices have constituted standard care for over 25 years. Contemporary literature reveals biomechanical and radiographic advantages that reduce revisions and downstream costs—the very metrics insurers prioritize. Major societies including the American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), North American Spine Society (NASS) and the Scoliosis Research Society have issued the new unified statement urging coverage aligned with evidence.

In a field where consensus is notoriously difficult, achieving near-unanimous agreement across these leading organizations is no small feat.

What About the Patient-Surgeon Relationship?

Restrictive policies erode more than access. They undermine the surgeon–patient relationship, the foundation of ethical medicine. The solution is not to remove all oversight but to require payers to ground coverage decisions in the same peer-reviewed literature and professional consensus that guide every other aspect of surgical practice.

Luis Tumialán MD, a neurosurgeon and Chair of the AANS/CNS Section on the Disorders of the Spine and Peripheral Nerves notes the following:

“Spine surgery is not a menu where an insurance company gets to choose the cheapest ingredients. The decision about what goes into a patient’s body belongs to the patient and the surgeon — full stop. When a payer denies access to an interbody implant that that has become part of the standard of care after a quarter century of use, they are no longer managing costs — they are practicing medicine without a license. Such a coverage determination policy is not just inappropriate — it is completely unacceptable.”

Spine surgeons should not be given carte blanche. But there is some recognition that interbody biomechanical devices are safe, effective, and often superior tools in the modern ACDF toolbox. Patients, at the insurance level, are paying customers and deserve the full range of clinically appropriate choices.

In the end, if payors do not align their policies with evidence and the unanimous position of the specialty societies, who should be responsible for the patient outcomes?